Candel Therapeutics, Inc.

NasdaqGM CADL

Candel Therapeutics, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 196.33

Candel Therapeutics, Inc. Price to Sales Ratio (P/S) is 196.33 on January 14, 2025, a 856.48% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Candel Therapeutics, Inc. 52-week high Price to Sales Ratio (P/S) is 249.42 on December 19, 2024, which is 27.04% above the current Price to Sales Ratio (P/S).
Candel Therapeutics, Inc. 52-week low Price to Sales Ratio (P/S) is 20.03 on January 26, 2024, which is -89.80% below the current Price to Sales Ratio (P/S).
Candel Therapeutics, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 99.77.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGM: CADL

Candel Therapeutics, Inc.

CEO	Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.
IPO Date	July 27, 2021
Location	United States
Headquarters	117 Kendrick Street
Employees	42
Sector	Health Care
Industries Clinical Trials Biotechnology Pharmaceuticals

Description

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.

Key trends

Past 5 years